FDA gets power to flood market with cheap foreign drugs during shortages

What it does

This bill allows the FDA to temporarily authorize imports of prescription drugs from approved foreign countries when there is a drug shortage or a 'marginally competitive market' (fewer than 5 competitors available for 10+ years after patent expiration). Importers can bring in foreign-approved drugs with the same active ingredient as the shortage drug for up to 3 years, provided the foreign manufacturer commits to seeking U.S. approval. The bill also requires annual reporting on drug shortages and import authorizations.

Why we flagged it

The bill's core mechanism is a temporary import pathway for prescription drugs during shortages or low-competition markets. It is a regulatory flexibility measure designed to increase supply and competition, not a commemorative or appropriations instrument.

What the text implies

• Foreign drug imports may undercut domestic manufacturers' pricing power, potentially reducing R&D investment incentives for new drugs if the import pathway becomes routine rather than emergency-only.
• The 'marginally competitive market' definition (fewer than 5 competitors, 10+ years post-patent) may inadvertently create a loophole for generic manufacturers to avoid competition by discontinuing products, triggering import authority.
• FDA's discretionary denial authority (safety/effectiveness) is broad but lacks explicit timeline or appeal process, potentially creating uncertainty for importers and delaying relief during acute shortages.
• Annual reporting requirement may reveal patterns of chronic shortages in specific therapeutic areas, exposing gaps in domestic manufacturing capacity or market consolidation.

Who it affects

Ordinary patients facing drug shortages or high prices due to limited competition gain access to lower-cost alternatives from approved foreign markets. The bill creates a safety valve when domestic supply is constrained or competition is artificially thin, potentially lowering out-of-pocket costs and improving access. The FDA retains authority to deny imports if safety concerns exist.

Who stands to gain

• generic drug manufacturers (foreign)
• drug importers/wholesalers
• patients and insurers (lower drug costs)
• pharmacy benefit managers (PBMs)

Named in the bill

FDA (Food and Drug Administration), Section 503 (Federal Food, Drug, and Cosmetic Act), Section 505 (drug approval pathway), Section 802 (list of approved foreign countries), Section 804 (importation definition), Section 506C (drug shortage authority), generic drug manufacturers, pharmaceutical importers

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Jul 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 17, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.